Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation

Heart

Volumn 104, Issue 8, 2018, Pages 644-651

  Ochiai, Tomoki ^a   Saito, Shigeru ^a   Yamanaka, Futoshi ^a   Shishido, Koki ^a   Tanaka, Yutaka ^a   Yamabe, Tsuyoshi ^a   Shirai, Shinichi ^b   Tada, Norio ^c   Araki, Motoharu ^d   Naganuma, Toru ^e   Watanabe, Yusuke ^f   Yamamoto, Masanori ^g,h   Hayashida, Kentaro ⁱ  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^b KOKURA MEMORIAL HOSPITAL   (Japan)

^c SENDAI KOUSEI HOSPITAL   (Japan)

^d SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^e NEW TOKYO HOSPITAL   (Japan)

^f TEIKYO UNIVERSITY   (Japan)

^g Toyohashi Heart Center Toyohashi   (Japan)

^h Nagoya Heart Center   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; aortic valve stenosis; renin angiotensin system; transcatheter aortic valve replacement

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; STATINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; BODY MASS; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; MULTICENTER STUDY; OUTPATIENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURGICAL RISK; SURVIVAL RATE; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VERY ELDERLY; AORTIC VALVE STENOSIS; CLINICAL TRIAL; EPIDEMIOLOGY; HEART VALVE PROSTHESIS; KAPLAN MEIER METHOD; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE STENOSIS; FEMALE; HEART VALVE PROSTHESIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 85044822998     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2017-311738     Document Type: Article

References (30)

1. Une D, Mesana L, Chan V, et al. Clinical impact of changes in left ventricular function after aortic valve replacement: analysis from 3112 patients. Circulation 2015;132:741-7.
2. L und O, Erlandsen M, Dørup I, et al. Predictable changes in left ventricular mass and function during ten years after valve replacement for aortic stenosis. J Heart Valve Dis 2004;13:357-68.
3. L im E, Ali A, Theodorou P, et al. Longitudinal study of the profile and predictors of left ventricular mass regression after stentless aortic valve replacement. Ann Thorac Surg 2008;85:2026-9.
4. Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol 2010;106:713-9.
5. Yiu KH, Ng WS, Chan D, et al. Improved prognosis following renin-angiotensinaldosterone system blockade in patients undergoing concomitant aortic and mitral valve replacement. Int J Cardiol 2014;177:680-2.
6. G oel SS, Aksoy O, Gupta S, et al. Renin-angiotensin system blockade therapy after surgical aortic valve replacement for severe aortic stenosis: a cohort study. Ann Intern Med 2014;161:699-710.
7. S mith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
8. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014;63:1972-81.
9. L indman BR, Stewart WJ, Pibarot P, et al. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv 2014;7:662-73.
10. Kodali S, Pibarot P, Douglas PS, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J 2015;36:449-56.
11. H ayashida K, Lefèvre T, Chevalier B, et al. Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012;5:1247-56.
12. Yamamoto M, Shimura T, Kano S, et al. Impact of preparatory coronary protection in patients at high anatomical risk of acute coronary obstruction during transcatheter aortic valve implantation. Int J Cardiol 2016;217:58-63.
13. L ang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography 2015;28:1-39.
14. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23.
15. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012;33:2403-18.
16. H ein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91.
17. L und O, Emmertsen K, Dørup I, et al. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J 2003;24:1437-46.
18. A li A, Patel A, Ali Z, et al. Enhanced left ventricular mass regression after aortic valve replacement in patients with aortic stenosis is associated with improved long-term survival. J Thorac Cardiovasc Surg 2011;142:285-91.
19. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensinconverting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
20. Benedetto U, Melina G, Refice S, et al. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch. Ann Thorac Surg 2010;90:1899-903.
21. S tewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
22. Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
23. C ONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
24. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
25. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
26. Panidis IP, Kotler MN, Ren JF, et al. Development and regression of left ventricular hypertrophy. J Am Coll Cardiol 1984;3:1309-20.
27. Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J 2016;37:2252-62.
28. E lder DH, Wei L, Szwejkowski BR, et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 2011;58:2084-91.
29. E we SH, Muratori M, Delgado V, et al. Hemodynamic and clinical impact of prosthesispatient mismatch after transcatheter aortic valve implantation. J Am Coll Cardiol 2011;58:1910-8.
30. Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesispatient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort-a analysis. J Am Coll Cardiol 2014;64:1323-34.